Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:EDGENASDAQ:GNPXNASDAQ:KTOVNASDAQ:MYOS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$2.09-3.7%$1.61$0.76▼$14.00$8.46M1.485.28 million shs50,584 shsEDGEEdge Therapeutics$2.90+6.6%$4.11$0.28▼$17.38$91.38M3.65373,201 shs1.13 million shsGNPXGenprex$2.35+5.9%$3.67$2.18▼$45.20$4.49M-0.6173,817 shs8,971 shsKTOVPurple Biotech$0.46+7.0%$4.16$2.20▼$14.40$7.25M2.371.18 million shs171,410 shsMYOSMYOS RENS Technology$3.35$0.74▼$3.85$16.70M1.081.68 million shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals-6.47%-27.18%+31.52%+64.39%-71.05%EDGEEdge Therapeutics+3.57%-7.94%-39.01%-32.40%-57.85%GNPXGenprex0.00%-20.50%-34.62%-73.56%-94.42%KTOVPurple Biotech+6.15%-25.04%-35.01%-29.08%-77.51%MYOSMYOS RENS Technology0.00%0.00%-2.14%-55.37%+358.19%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEDGEEdge TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex4.1923 of 5 stars3.55.00.04.70.60.81.3KTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/AEDGEEdge TherapeuticsN/AN/AN/AN/AGNPXGenprex3.00Buy$10.00325.53% UpsideKTOVPurple BiotechN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/ACurrent Analyst RatingsLatest ADIL, MYOS, KTOV, EDGE, and GNPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/AEDGEEdge TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AGNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AKTOVPurple Biotech$1M7.25N/AN/A$5.56 per share0.08MYOSMYOS RENS Technology$1.03M0.00N/AN/A$0.13 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)EDGEEdge Therapeutics-$40.86MN/A0.00∞N/AN/A-81.29%-56.92%N/AGNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS Technology-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AEDGEEdge TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90EDGEEdge TherapeuticsN/A5.595.59GNPXGenprexN/A2.312.31KTOVPurple BiotechN/A2.22N/AMYOSMYOS RENS Technology0.113.781.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%EDGEEdge Therapeutics28.04%GNPXGenprex14.05%KTOVPurple Biotech30.72%MYOSMYOS RENS Technology4.97%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%EDGEEdge Therapeutics37.10%GNPXGenprex11.54%KTOVPurple Biotech2.98%MYOSMYOS RENS Technology45.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals164.05 million3.47 millionNo DataEDGEEdge TherapeuticsN/A31.51 millionN/ANot OptionableGNPXGenprex311.91 million1.69 millionOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableMYOSMYOS RENS Technology1512.19 millionN/ANot OptionableADIL, MYOS, KTOV, EDGE, and GNPX HeadlinesSourceHeadlineRen Zhengfei says US government 'underestimates' Huaweibbc.com - December 23 at 1:17 PMPioneer announces The Ren as Business Partner of the Yearrichlandsource.com - November 20 at 1:50 PMShenqiang Renbuffalo.edu - October 4 at 3:32 PMAnthony M. Newman to Lead REN-ISAC Cybersecurity Centercampustechnology.com - August 27 at 9:26 PMCarbon-based quantum technologysciencedaily.com - August 19 at 4:05 PMBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]marketwatch.com - May 11 at 1:13 AMLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraintsmarketwatch.com - May 8 at 9:06 PMBio-active Peptides Market Size Dynamics 2023-2029marketwatch.com - April 13 at 3:09 PMRenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platformcointelegraph.com - April 6 at 1:03 PMGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027marketwatch.com - March 21 at 9:47 AMBio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027marketwatch.com - March 13 at 10:33 AMCan Huawei thrive despite American sanctions?economist.com - October 29 at 10:12 AMBio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028marketwatch.com - September 28 at 9:57 AMBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries Datamarketwatch.com - August 4 at 1:49 AMRenaissance Festival tickets go on sale Friday, Aug. 5independenttribune.com - August 1 at 9:38 AMRensair raises $7m to establish clean air as a human rightwfmz.com - May 10 at 9:43 AMBioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026wicz.com - January 12 at 2:06 PMBioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.chipdesignmag.com - November 1 at 10:13 PMICYMI: Everything you need to know about the iPhone 13yahoo.com - September 26 at 10:38 PMMYOS RENS Technology Inc. Common Stock (MYOS)nasdaq.com - July 29 at 10:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioBanks Think Small Cap Stocks Need to Catch Up: 3 WinnersApril 3, 2024 8:54 AMView Banks Think Small Cap Stocks Need to Catch Up: 3 WinnerseBay Steadily Climbs as Collectors Drive Growth March 25, 2024 6:29 AMView eBay Steadily Climbs as Collectors Drive Growth 3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Edge TherapeuticsNASDAQ:EDGEPDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.MYOS RENS TechnologyNASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.